Gene-Edited Brain Organoids Are Unlocking the Secrets of Autism
By Amit Katwala,
Wired
| 02. 21. 2022
Hundreds of genes have been linked to autism spectrum disorder (ASD), a complicated range of conditions affecting the behavior, social development, and communication of tens of millions people worldwide. But teasing out exactly what effect those genes have and how they relate to ASD has been devilishly difficult. “Nobody can study an actual human brain as it develops,” says Paola Arlotta, a professor of stem cell and regenerative biology at Harvard University. But a new approach based on growing clumps of brain cells in the lab is now yielding promising results.
Arlotta and her colleagues at Harvard and the Broad Institute of Harvard and MIT have been working with organoids—three-dimensional clumps of brain tissue grown from stem cells—usually just a few millimeters across. When organoids are left to grow, they start to develop different types of brain cells, and begin to organize into primitive networks that mimic some, but not all, of the architecture of the human brain.
Organoids grown from stem cells donated by people with ASD have been used to study the condition in the past. But... see more
Related Articles
By Sarah Zhang, The Atlantic | 06.22.2022
Photo by ANIRUDH on Unsplash
In October 2019, Jordan Janz became the first person in the world to receive an experimental therapy for cystinosis, a rare genetic disease. The treatment was physically grueling. Doctors extracted blood stem cells from Janz’s...
By Ian Sample , The Guardian | 06.22.2022
More than half the UK backs the idea of rewriting the DNA of human embryos to prevent severe or life-threatening diseases, according to a survey.
Commissioned by the Progress Educational Trust (PET), a fertility and genomics charity, the Ipsos poll...
By Fiorella Valdesolo, WSJ Magazine | 06.08.2022
“Where is the we?” It’s the question that was the driving force for Vida Delrahim and Ronit Menashe when they created WeNatal, a new brand of prenatal supplements that aims to be more inclusive. In the process of trying...
By Michael Le Page, New Scientist | 06.16.2022
CRISPR gene-editing trials for treating sickle cell disease and beta thalassaemia are being extended to include children aged under 12 after the therapies proved successful in ongoing trials involving people aged between 12 and 35. The aim is to treat...